Showing 2701-2710 of 5258 results for "".
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- National Psoriasis Foundation Honors Dr. Jerry Bagel with Excellence in Leadership Awardhttps://practicaldermatology.com/news/national-psoriasis-foundation-honors-dr-jerry-bagel-with-excellence-in-leadership-award/2457766/Jerry Bagel, MD, an internationally recognized expert in the treatment of psoriasis and founder of Windsor Dermatology and Psoriasis Treatment Center of Central New Jersey, will receive the Excellence in Leadership Award from the National Psoriasis Foundation (NPF) next month. For more th
- SENTÉ Launches Illuminé Eye Creamhttps://practicaldermatology.com/news/sent-launches-illumin-eye-cream/2457774/SENTÉ® Illuminé Eye Cream to help diminish the appearance of redness and periorbital discoloration is now available. The formulation also improves the appearance of wrinkles and crepiness, as well as the appearance of puffiness, the company says.
- Innovations in Skin of Color Dermatology Award Goes to Eliot Battle, MDhttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-goes-to-eliot-battle-md/2457775/Eliot Battle, MD has been awarded the Innovations in Skin of Color Dermatology Award. The award was presented by The&nbs
- Study Seeks to Harness the Power of Probiotics to Treat Eczemahttps://practicaldermatology.com/news/study-seeks-to-harness-the-power-of-probiotics-to-treat-eczema/2457778/A new clinical trial is investigating whether beneficial bacteria can help treat eczema by restoring the natural microbial balance of healthy skin. "There are over 1,000 species of bacteria that all live in balance on healthy skin, some that even produce natural antibiotics. However,
- AAD Launches Campaign to Support Skin Self Examshttps://practicaldermatology.com/news/aad-launches-campaign-to-support-skin-self-exams/2457782/In recognition of Skin Cancer Awareness Month in May and Melanoma Monday® on May 7, the American Academy of Dermatology is encouraging the public to be a “Skin Can
- Bath Emollients Don't Add Much to Standard Eczema Carehttps://practicaldermatology.com/news/bath-emollients-dont-add-much-to-standard-eczema-care/2457784/Emollient bath additives provide no meaningful benefit when used in addition to standard eczema care in children, according to research in the BMJ. UK researchers, led by Miriam Santer, MBBChir
- Encore Dermatology Launches Impoyz Cream 0.025%, a Newly Formulated High-Potency Topical Corticosteroidhttps://practicaldermatology.com/news/encore-dermatology-launches-impoyz-cream-0025-a-newly-formulated-high-potency-topical-corticosteroid/2457787/Encore Dermatology Inc. launched its new topical product, Impoyz Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate. &ld
- New Phase 4 Data: Epiduo Forte Gel Decreased Acne Lesions, Reduced Risk of Scarshttps://practicaldermatology.com/news/new-phase-4-data-epiduo-forte-gel-decreased-acne-lesions-reduced-risk-of-scars/2457788/Results from OSCAR, a Phase 4, multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left half-face), revealed that Epiduo Forte (adapalene and benzoyl peroxide) Gel 0.3%/2.5% not only decreased acne lesions, as measured over a period of